THERAPY DOSSIER · th-d58f014811d5

PGI-02776 (NAAG peptidase inhibitor prodrug of ZJ-43)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21565332 ↗2011Reported benefit

Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI.

RatTBIFluid percussionSprague-DawleyMaleintraperitoneal10 mg/kg30 min after injury

Model: lateral fluid percussion TBI

Post-injury PGI-02776 (10 mg/kg) reduced hippocampal neuronal degeneration and improved cognitive performance after TBI.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…